title: Preoperative radiation with concurrent 5-fluorouracil continuous infusion for locally advanced unresectable rectal cancer.
abstract: OBJECTIVE
  To determine the percentage of complete responders and the resectability rate for patients with locally advanced carcinoma of the rectum treated by 5-fluorouracil (5-FU) infusional chemotherapy and pelvic radiation.
  
  
  METHODS
  Between October 1992 and June 1996, 29 patients with a diagnosis of locally advanced unresectable rectal cancer received preoperative 5 FU by continuous intravenous infusion at a dose of 225 mg/m2/day concurrent with pelvic radiation (median 54 Gy/28 fractions). All patients were clinical stage T4 on the bases of organ invasion or tumor fixation. Median time for surgical resection was 6 weeks.
  
  
  RESULTS
  Median follow-up for the group was 28 months (range 5-57 months). Six patients were felt to be persistently unresectable or developed distant metastases and did not undergo surgical resection. Of the 29 patients, 23 proceeded to surgery, 18 were resectable for cure, 13 by abdominoperineal resection, 3 by anterior resection and 2 by local excision. Of the 29 patients, 4 (13%) had a complete response, and 90% were clinically downstaged. Of the 18 resected patients, 1 has died of his disease, 17 are alive, and 15 disease-free. The regimen was well tolerated; there was only one treatment-related complication, a wound dehiscence.
  
  
  CONCLUSIONS
  The combination of 5 FU infusion and pelvic radiation in the management of locally advanced rectal cancer is well tolerated and provides a baseline for comparison purposes with future combinations of newer systemic agents and radiation.
authors.affiliation: London Regional Cancer Center, University of Western Ontario, Canada.
authors.forename: G M
authors.initials: GM
authors.lastname: Videtic
authors.forename: B J
authors.initials: BJ
authors.lastname: Fisher
authors.forename: F E
authors.initials: FE
authors.lastname: Perera
authors.forename: G S
authors.initials: GS
authors.lastname: Bauman
authors.forename: W I
authors.initials: WI
authors.lastname: Kocha
authors.forename: M
authors.initials: M
authors.lastname: Taylor
authors.forename: M D
authors.initials: MD
authors.lastname: Vincent
authors.forename: E A
authors.initials: EA
authors.lastname: Plewes
authors.forename: C J
authors.initials: CJ
authors.lastname: Engel
authors.forename: L W
authors.initials: LW
authors.lastname: Stitt
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use*; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D011879:Radiotherapy Dosage; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery
chemical_list: D000964:Antimetabolites, Antineoplastic; D005472:Fluorouracil